Filing Details
- Accession Number:
- 0001209191-16-121349
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-05-18 17:15:28
- Reporting Period:
- 2016-05-16
- Filing Date:
- 2016-05-18
- Accepted Time:
- 2016-05-18 17:15:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 906709 | Nektar Therapeutics | NKTR | Pharmaceutical Preparations (2834) | 943134940 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1480111 | K Stephen Doberstein | C/O Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco CA 94158 | Svp & Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-05-16 | 875 | $0.00 | 1,360 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-05-17 | 339 | $13.58 | 1,021 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2016-05-16 | 875 | $0.00 | 875 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 8,750 | 2016-05-16 | 2016-05-16 | No | 4 | D | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $13.27 to $13.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Billionaire Hedge Funds
